Corient Private Wealth
CLDX icon

Corient Private Wealth’s Celldex Therapeutics CLDX Stock Holding History

Corient Private Wealth’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.58M Buy
176,956
+162,320
+1,109% +$5.24M 0.01% 792
2026
Q1 		$393K Sell
14,636
-220,062
-94% -$6M ﹤0.01% 2161
2025
Q4 		$6.21M Sell
234,698
-4,908
-2% -$129K 0.01% 703
2025
Q3 		$6.21M Buy
239,606
+37,889
+19% +$878K 0.01% 645
2025
Q2 		$4.1M Buy
+201,717
New +$3.93M 0.01% 761

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's CLDX Position: Q2 2026 in Review

Corient Private Wealth increased its Celldex Therapeutics (CLDX) stake by 1,109% in Q2 2026, buying an estimated $5.24M and bringing the position to 176,956 shares worth $6.58M. The position accounts for 0.01% of the portfolio, ranked #792.

Corient Private Wealth first reported a position in CLDX in Q2 2025 and has held it in 5 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Corient Private Wealth held 176,956 shares of Celldex Therapeutics worth $6.58M as of Q2 2026.
  • Corient Private Wealth bought 162,320 Celldex Therapeutics shares in Q2 2026, an estimated $5.24M.
  • Celldex Therapeutics made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #792 holding.
  • Corient Private Wealth first reported a position in Celldex Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.